Osman I - Search Results

1

Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.

Nuñez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, Gonen M, Riedel E, Scher HI, Larson SM. Nuñez R, et al. Among authors: osman i. J Nucl Med. 2002 Jan;43(1):46-55. J Nucl Med. 2002. PMID: 11801702 Free article.

2

Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer.

Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K, Verbel D, Schwartz L, Larson SM, Scher HI. Morris MJ, et al. Among authors: osman i. Urology. 2002 Jun;59(6):913-8. doi: 10.1016/s0090-4295(02)01509-1. Urology. 2002. PMID: 12031380

3

Differential Metabolism and Pharmacokinetics of L-[1-(11)C]-Methionine and 2-[(18)F] Fluoro-2-deoxy-D-glucose (FDG) in Androgen Independent Prostate Cancer.

Macapinlac HA, Humm JL, Akhurst T, Osman I, Pentlow K, Shangde C, Yeung HW, Squire O, Finn RD, Scher HI, Larson SM. Macapinlac HA, et al. Among authors: osman i. Clin Positron Imaging. 1999 May;2(3):173-181. doi: 10.1016/s1095-0397(99)00015-1. Clin Positron Imaging. 1999. PMID: 14516541

4

Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone.

Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Drobnjak M, et al. Among authors: osman i. Clin Cancer Res. 2000 May;6(5):1891-5. Clin Cancer Res. 2000. PMID: 10815912

5

HER-2 profiling and targeting in prostate carcinoma.

Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI. Morris MJ, et al. Among authors: osman i. Cancer. 2002 Feb 15;94(4):980-6. Cancer. 2002. PMID: 11920466 Free article. Clinical Trial.

6

Inactivation of the p53 pathway in prostate cancer: impact on tumor progression.

Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI, Cordon-Cardo C. Osman I, et al. Clin Cancer Res. 1999 Aug;5(8):2082-8. Clin Cancer Res. 1999. PMID: 10473090

7

HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.

Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, Agus D, Ross JS, Cordon-Cardo C. Osman I, et al. Clin Cancer Res. 2001 Sep;7(9):2643-7. Clin Cancer Res. 2001. PMID: 11555574

8

Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.

Lee CT, Capodieci P, Osman I, Fazzari M, Ferrara J, Scher HI, Cordon-Cardo C. Lee CT, et al. Among authors: osman i. Clin Cancer Res. 1999 May;5(5):977-83. Clin Cancer Res. 1999. PMID: 10353729

9

The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer.

Kelly WK, Osman I, Reuter VE, Curley T, Heston WD, Nanus DM, Scher HI. Kelly WK, et al. Among authors: osman i. Clin Cancer Res. 2000 Mar;6(3):838-46. Clin Cancer Res. 2000. PMID: 10741705 Clinical Trial.

10

Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent.

Osman I, Sherman E, Singh B, Venkatraman E, Zelefsky M, Bosl G, Scher H, Shah J, Shaha A, Kraus D, Cordon-Cardo C, Pfister DG. Osman I, et al. J Clin Oncol. 2002 Jul 1;20(13):2980-7. doi: 10.1200/JCO.2002.06.161. J Clin Oncol. 2002. PMID: 12089228

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

427 results

Search Page

Filters